{"denoms":[{"counts":[{"groupId":"BG000","value":"229"},{"groupId":"BG001","value":"242"},{"groupId":"BG002","value":"471"}],"units":"Participants"}],"groups":[{"description":"Patients receive dexamethasone PO QD on days 1, 8, 15, and 22 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nDexamethasone: Given PO\n\nLaboratory Biomarker Analysis: Optional correlative studies\n\nLenalidomide: Given PO","id":"BG000","title":"Arm I (Dexamethasone and Lenalidomide)"},{"description":"Patients receive dexamethasone PO QD on days 1, 2, 4, 5, 8, 9, 11, and 12; lenalidomide PO QD on days 1-14; and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given IV\n\nDexamethasone: Given PO\n\nLaboratory Biomarker Analysis: Optional correlative studies\n\nLenalidomide: Given PO","id":"BG001","title":"Arm II (Dexamethasone, Lenalidomide, Bortezomib)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"269"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"202"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"196"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"122"},{"groupId":"BG001","value":"153"},{"groupId":"BG002","value":"275"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"164"},{"groupId":"BG002","value":"314"}],"title":"ISS Stage I or II"},{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"157"}],"title":"ISS Stage III"}]}],"description":"International Staging System (ISS) Criteria:\n\nStage I: Serum β2-microglobulin \\< 3.5mg/L and Serum Albumin ≥ 3.5 g/dL; expected median survival is 62 months. Stage II\\*: Not Stage I or III; expected median survival is 44 months. Stage III: Serum β2-microglobulin \\> 5.5 mg/L; expected median survival is 29 months.\n\n\\*There are two categories for stage II: serum β2-microglobulin \\< 3.5 mg/L but serum albumin \\< 3.5 g/dL; or serum β2-microglobulin 3.5 to \\< 5.5 mg/L irrespective of the serum albumin level.","paramType":"COUNT_OF_PARTICIPANTS","title":"ISS Stage","unitOfMeasure":"Participants"}],"populationDescription":"Includes all eligible and analyzable patients."}